-
Je něco špatně v tomto záznamu ?
Expression of p53, p21 and p16 does not correlate with response to preoperative chemoradiation in gastric carcinoma
I. Sirák, J. Petera, J. Hatlová, M. Vošmik, B. Melichar, J. Dvořák, V. Tyčová, Z. Zoul, M. Leško
Jazyk angličtina Země Řecko
Typ dokumentu práce podpořená grantem
- MeSH
- celková dávka radioterapie MeSH
- dospělí MeSH
- financování organizované MeSH
- imunohistochemie MeSH
- inhibitor p21 cyklin-dependentní kinasy metabolismus MeSH
- karcinom metabolismus patologie terapie MeSH
- kombinovaná terapie MeSH
- lidé středního věku MeSH
- lidé MeSH
- nádorové proteiny metabolismus MeSH
- nádory žaludku metabolismus patologie MeSH
- předoperační péče MeSH
- protokoly protinádorové kombinované chemoterapie terapeutické užití MeSH
- retrospektivní studie MeSH
- rozdělení chí kvadrát MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- staging nádorů MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- práce podpořená grantem MeSH
BACKGROUND/AIMS: A retrospective evaluation was oerformed to determine whether the intensity of p53, p21 or p16 expression predicts response to preoperative chemoradiotherapy in locally advanced gastric carcinoma. METHODOLOGY: Thirty-six patients (cT2-4 or N+) were studied. Preoperative treatment consisted of 30-45Gy of radiation with continuous 5-fluorouracil and weekly cisplatin. Expression of p53, p21 and p16 in pretreatment biopsies was assessed by immunohistochemistry. Level of expression was determined from the intensity and extent of staining. Tumor downstaging was defined as a reduction of at least one T-stage level and/or finding of intense tumor regression in histopathologic examination. RESULTS: Seventeen patients responded to chemoradiation: 8 patients had pathologic complete response, 9 patients were downstaged. The multivariate analysis showed no significant influence of p53 (p = 0.76), p21 (p = 0.10) nor p16 (p = 0.70) expression upon tumor response. Response was found in 52% of patients with low, and in 40% of patients with high p53 staining (p = 0.21); in 54% of patients with low, and in 30% of patients with high p21 staining (p = 0.14); and in 48% of patients with low, and in 43% of patients with high p16 staining (p = 0.32). CONCLUSIONS: We found no significant influence of p53, p21 nor p16 expression upon response to preoperative chemoradiotherapy in gastric carcinoma.
- 000
- 03666naa 2200601 a 4500
- 001
- bmc11022418
- 003
- CZ-PrNML
- 005
- 20120501202137.0
- 008
- 110729s2009 gr e Eng||
- 009
- AR
- 040 __
- $a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a gr
- 100 1_
- $a Sirák, Igor $7 xx0135409
- 245 10
- $a Expression of p53, p21 and p16 does not correlate with response to preoperative chemoradiation in gastric carcinoma / $c I. Sirák, J. Petera, J. Hatlová, M. Vošmik, B. Melichar, J. Dvořák, V. Tyčová, Z. Zoul, M. Leško
- 314 __
- $a Department of Oncology and Radiotherapy, Charles University Medical School and University Hospital, Hradec Kralove, Czech Republic. sirak@fnhk.cz
- 520 9_
- $a BACKGROUND/AIMS: A retrospective evaluation was oerformed to determine whether the intensity of p53, p21 or p16 expression predicts response to preoperative chemoradiotherapy in locally advanced gastric carcinoma. METHODOLOGY: Thirty-six patients (cT2-4 or N+) were studied. Preoperative treatment consisted of 30-45Gy of radiation with continuous 5-fluorouracil and weekly cisplatin. Expression of p53, p21 and p16 in pretreatment biopsies was assessed by immunohistochemistry. Level of expression was determined from the intensity and extent of staining. Tumor downstaging was defined as a reduction of at least one T-stage level and/or finding of intense tumor regression in histopathologic examination. RESULTS: Seventeen patients responded to chemoradiation: 8 patients had pathologic complete response, 9 patients were downstaged. The multivariate analysis showed no significant influence of p53 (p = 0.76), p21 (p = 0.10) nor p16 (p = 0.70) expression upon tumor response. Response was found in 52% of patients with low, and in 40% of patients with high p53 staining (p = 0.21); in 54% of patients with low, and in 30% of patients with high p21 staining (p = 0.14); and in 48% of patients with low, and in 43% of patients with high p16 staining (p = 0.32). CONCLUSIONS: We found no significant influence of p53, p21 nor p16 expression upon response to preoperative chemoradiotherapy in gastric carcinoma.
- 590 __
- $a bohemika - dle Pubmed
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a senioři nad 80 let $7 D000369
- 650 _2
- $a protokoly protinádorové kombinované chemoterapie $x terapeutické užití $7 D000971
- 650 _2
- $a karcinom $x metabolismus $x patologie $x terapie $7 D002277
- 650 _2
- $a rozdělení chí kvadrát $7 D016009
- 650 _2
- $a kombinovaná terapie $7 D003131
- 650 _2
- $a inhibitor p21 cyklin-dependentní kinasy $x metabolismus $7 D050759
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a imunohistochemie $7 D007150
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a nádorové proteiny $x metabolismus $7 D009363
- 650 _2
- $a staging nádorů $7 D009367
- 650 _2
- $a předoperační péče $7 D011300
- 650 _2
- $a celková dávka radioterapie $7 D011879
- 650 _2
- $a nádory žaludku $x metabolismus $x patologie $7 D013274
- 650 _2
- $a Stomach Neoplasms $x th [Therapy]
- 650 _2
- $a Tumor Markers, Biological $x me [Metabolism]
- 650 _2
- $a Tumor Suppressor Protein p53 $x me [Metabolism]
- 650 _2
- $a financování organizované $7 D005381
- 650 _2
- $a retrospektivní studie $7 D012189
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Petera, Jiří, $d 1959- $7 xx0000229
- 700 1#
- $a Hatlová, Jana. $7 xx0227931
- 700 1_
- $a Vošmik, Milan, $d 1972- $7 xx0135408
- 700 1_
- $a Melichar, Bohuslav, $d 1965- $7 skuk0000853
- 700 1_
- $a Dvořák, Josef, $d 1966- $7 xx0072583
- 700 1_
- $a Tyčová, Věra $7 xx0107794
- 700 1#
- $a Zoul, Zdeněk. $7 xx0041328
- 700 1_
- $a Leško, Michal, $d 1955-2019 $7 xx0063978
- 773 0_
- $t Hepato-Gastroenterology $w MED00002025 $g Roč. 56, č. 93 (2009), s. 1213-1218 $x 0172-6390
- 910 __
- $a ABA008 $b x $y 2
- 990 __
- $a 20110802082559 $b ABA008
- 991 __
- $a 20120501202203 $b ABA008
- 999 __
- $a ok $b bmc $g 881793 $s 732345
- BAS __
- $a 3
- BMC __
- $a 2009 $x MED00002025 $b 56 $c 93 $d 1213-1218 $i 0172-6390 $m Hepato-gastroenterology $n Hepatogastroenterology
- LZP __
- $a 2011-4B09/jvme